KR101420211B1 - Skin Composition for External Application Using Bud and Sprout Extract - Google Patents
Skin Composition for External Application Using Bud and Sprout Extract Download PDFInfo
- Publication number
- KR101420211B1 KR101420211B1 KR1020120072130A KR20120072130A KR101420211B1 KR 101420211 B1 KR101420211 B1 KR 101420211B1 KR 1020120072130 A KR1020120072130 A KR 1020120072130A KR 20120072130 A KR20120072130 A KR 20120072130A KR 101420211 B1 KR101420211 B1 KR 101420211B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- sprout
- skin
- composition
- bud
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 111
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 17
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims abstract description 12
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims abstract description 12
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims abstract description 12
- 244000223014 Syzygium aromaticum Species 0.000 claims abstract description 10
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims abstract description 10
- 239000001140 aloe barbadensis leaf extract Substances 0.000 claims abstract description 5
- 229940059958 centella asiatica extract Drugs 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 244000269722 Thea sinensis Species 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000006071 cream Substances 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 239000002537 cosmetic Substances 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 235000016709 nutrition Nutrition 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 241001474374 Blennius Species 0.000 claims description 2
- 244000146462 Centella asiatica Species 0.000 claims description 2
- 235000004032 Centella asiatica Nutrition 0.000 claims description 2
- 239000004902 Softening Agent Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 abstract description 18
- 240000002791 Brassica napus Species 0.000 abstract description 11
- 235000006008 Brassica napus var napus Nutrition 0.000 abstract description 4
- 241000234282 Allium Species 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 44
- 230000000694 effects Effects 0.000 description 18
- 230000035784 germination Effects 0.000 description 14
- 102000008186 Collagen Human genes 0.000 description 11
- 108010035532 Collagen Proteins 0.000 description 11
- 229920001436 collagen Polymers 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 239000001301 oxygen Substances 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 239000003963 antioxidant agent Substances 0.000 description 8
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- -1 1 O 2) Chemical compound 0.000 description 7
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 235000013399 edible fruits Nutrition 0.000 description 7
- 210000002514 epidermal stem cell Anatomy 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 210000002510 keratinocyte Anatomy 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000009759 skin aging Effects 0.000 description 7
- 235000013616 tea Nutrition 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 241001116389 Aloe Species 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 235000011399 aloe vera Nutrition 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 5
- 244000046052 Phaseolus vulgaris Species 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000003642 reactive oxygen metabolite Substances 0.000 description 5
- 210000004927 skin cell Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000037303 wrinkles Effects 0.000 description 5
- RIXNFYQZWDGQAE-DFHVBEEKSA-N (4as,6ar,6as,6br,8ar,10s,12ar,14bs)-10-acetyloxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound C([C@H]1C2=CC[C@H]34)C(C)(C)CC[C@]1(C(O)=O)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)C)C1(C)C RIXNFYQZWDGQAE-DFHVBEEKSA-N 0.000 description 4
- 244000144725 Amygdalus communis Species 0.000 description 4
- 244000068988 Glycine max Species 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- 235000020224 almond Nutrition 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 229960001948 caffeine Drugs 0.000 description 4
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000009569 green tea Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- 235000011437 Amygdalus communis Nutrition 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 208000020084 Bone disease Diseases 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 102100027881 Tumor protein 63 Human genes 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- DANYIYRPLHHOCZ-UHFFFAOYSA-N 5,7-dihydroxy-4'-methoxyflavone Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 DANYIYRPLHHOCZ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241001164374 Calyx Species 0.000 description 2
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 240000003553 Leptospermum scoparium Species 0.000 description 2
- 102000003820 Lipoxygenases Human genes 0.000 description 2
- 108090000128 Lipoxygenases Proteins 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000219793 Trifolium Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 241000219995 Wisteria Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- LFEUICHQZGNOHD-RECXWPGBSA-N biochanin A 7-O-beta-D-glucoside Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC(O)=C2C1=O LFEUICHQZGNOHD-RECXWPGBSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000011382 collagen catabolic process Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 229930013686 lignan Natural products 0.000 description 2
- 235000009408 lignans Nutrition 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- UWKAYLJWKGQEPM-LBPRGKRZSA-N linalyl acetate Chemical group CC(C)=CCC[C@](C)(C=C)OC(C)=O UWKAYLJWKGQEPM-LBPRGKRZSA-N 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- FPIOBTBNRZPWJW-UHFFFAOYSA-N pratensein Chemical compound C1=C(O)C(OC)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O FPIOBTBNRZPWJW-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000007845 reactive nitrogen species Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000036560 skin regeneration Effects 0.000 description 2
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- HGXBRUKMWQGOIE-AFHBHXEDSA-N (+)-pinoresinol Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-AFHBHXEDSA-N 0.000 description 1
- NQWVSMVXKMHKTF-JKSUJKDBSA-N (-)-Arctigenin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-JKSUJKDBSA-N 0.000 description 1
- MATGKVZWFZHCLI-LSDHHAIUSA-N (-)-matairesinol Chemical compound C1=C(O)C(OC)=CC(C[C@@H]2[C@H](C(=O)OC2)CC=2C=C(OC)C(O)=CC=2)=C1 MATGKVZWFZHCLI-LSDHHAIUSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 108010043797 4-alpha-glucanotransferase Proteins 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- YYGRXNOXOVZIKE-UHFFFAOYSA-N Arctigenin Natural products COC1CCC(CC2COC(=O)C2CC3CCC(O)C(C3)OC)CC1OC YYGRXNOXOVZIKE-UHFFFAOYSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 235000011303 Brassica alboglabra Nutrition 0.000 description 1
- 244000060924 Brassica campestris Species 0.000 description 1
- 240000000385 Brassica napus var. napus Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000011302 Brassica oleracea Nutrition 0.000 description 1
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 1
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 1
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241001573881 Corolla Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000266331 Eugenia Species 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 241000555712 Forsythia Species 0.000 description 1
- KFFCKOBAHMGTMW-LGQRSHAYSA-N Forsythin Chemical compound C1=C(OC)C(OC)=CC=C1[C@H]1[C@@H](CO[C@@H]2C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC=3)[C@@H]2CO1 KFFCKOBAHMGTMW-LGQRSHAYSA-N 0.000 description 1
- OIFFJDGSLVHPCW-UHFFFAOYSA-N Guayarol Natural products COc1ccc(CC2C(Cc3ccc(O)c(O)c3)COC2=O)cc1OC OIFFJDGSLVHPCW-UHFFFAOYSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- NQWVSMVXKMHKTF-UHFFFAOYSA-N L-Arctigenin Natural products C1=C(OC)C(OC)=CC=C1CC1C(CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 1
- 240000005819 Magnolia denudata Species 0.000 description 1
- PWUCIPXNTHJNJC-UHFFFAOYSA-N Matairesinoside Natural products COc1cc(CC2C(Cc3ccc(OC4OC(CO)C(O)C(O)C4O)c(OC)c3)CCC2=O)ccc1O PWUCIPXNTHJNJC-UHFFFAOYSA-N 0.000 description 1
- AAGCATAPYOEULE-UHFFFAOYSA-N Matairesinoside aglycone Natural products C1=C(O)C(OC)=CC(CC2C(C(=O)OC2)CC=2C=C(OC)C(OC3C(C(O)C(O)C(CO)O3)O)=CC=2)=C1 AAGCATAPYOEULE-UHFFFAOYSA-N 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- JJVGFDTWFVSBIM-UHFFFAOYSA-N Phillyrin Natural products COc1ccc(cc1OC)C2OCC3C2COC3c4ccc(OC)c(OC5OC(CO)C(O)C(O)C5O)c4 JJVGFDTWFVSBIM-UHFFFAOYSA-N 0.000 description 1
- 101710096328 Phospholipase A2 Proteins 0.000 description 1
- 102100026918 Phospholipase A2 Human genes 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000009962 acacetin Nutrition 0.000 description 1
- FBSKJMQYURKNSU-ZLSOWSIRSA-N acteoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FBSKJMQYURKNSU-ZLSOWSIRSA-N 0.000 description 1
- 229930185474 acteoside Natural products 0.000 description 1
- FBSKJMQYURKNSU-UKQWSTALSA-N acteoside I Natural products C[C@@H]1O[C@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](O)[C@H](O)[C@H]1O FBSKJMQYURKNSU-UKQWSTALSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 1
- 229940022757 asiaticoside Drugs 0.000 description 1
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008162 cooking oil Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- UWKAYLJWKGQEPM-UHFFFAOYSA-N linalool acetate Natural products CC(C)=CCCC(C)(C=C)OC(C)=O UWKAYLJWKGQEPM-UHFFFAOYSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 102100039604 mRNA guanylyltransferase Human genes 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 235000000055 matairesinol Nutrition 0.000 description 1
- RNXYRAQIZQGUIK-UHFFFAOYSA-N matairesinol Natural products COc1cc(CC2OCC(=O)C2Cc3ccc(O)c(OC)c3)ccc1O RNXYRAQIZQGUIK-UHFFFAOYSA-N 0.000 description 1
- AAGCATAPYOEULE-LHHMAMHXSA-N matairesinoside Chemical compound C1=C(O)C(OC)=CC(C[C@@H]2[C@H](C(=O)OC2)CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)=C1 AAGCATAPYOEULE-LHHMAMHXSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- NWFYESYCEQICQP-UHFFFAOYSA-N methylmatairesinol Natural products C1=C(OC)C(OC)=CC=C1CC1C(=O)OCC1CC1=CC=C(O)C(OC)=C1 NWFYESYCEQICQP-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 208000011309 nasal bleeding Diseases 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000019449 other food additives Nutrition 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000007221 pinoresinol Nutrition 0.000 description 1
- OHOPKHNWLCMLSW-UHFFFAOYSA-N pinoresinol Natural products C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(CO)C(O)=CC=3)CO2)=C1 OHOPKHNWLCMLSW-UHFFFAOYSA-N 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical class C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 1
- AHVGRDMMMLZUJT-FHDYCXBFSA-N sissotrin Natural products COc1ccc(cc1)C2=COc3cc(O[C@@H]4C[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)cc(O)c3C2=O AHVGRDMMMLZUJT-FHDYCXBFSA-N 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940092665 tea leaf extract Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- QFRYQWYZSQDFOS-UHFFFAOYSA-N verbascoside Natural products CC1OC(COC2C(O)C(COC3OC(C(O)C(O)C3O)C(=O)O)OC(Oc4cc(O)cc5OC(=CC(=O)c45)c6ccc(O)c(O)c6)C2O)C(O)C(O)C1O QFRYQWYZSQDFOS-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- BURBOJZOZGMMQF-UHFFFAOYSA-N xanthoxylol Natural products C1=C(O)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 BURBOJZOZGMMQF-UHFFFAOYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Birds (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 식물의 새싹 또는 새순추출물을 함유한 피부 외용제 조성물에 관한 것으로, 구체적으로는 밀싹, 브로콜리, 유채, 콩싹, 잇꽃, 클로브 등의 새싹추출물과 회화나무 꽃봉오리, 자목련 꽃봉오리, 차나무 잎 등의 새순추출물을 유효성분으로 포함하는 피부 외용제 조성물에 관한 것이다.
아울러 본 발명에 따른 피부 외용제 조성물에는 알로에 잎 추출물, 병풀 추출물 및 연교 추출물이 더 포함된다. The present invention relates to a composition for external application for skin containing a bud or an extract of a plant, and more particularly, to a composition for external application for skin comprising bud extract, broccoli, oilseed rape, sprout, safflower, clove and the like, As an active ingredient, to a composition for external application for skin.
In addition, the composition for external application for skin according to the present invention further includes aloe leaf extract, Centella asiatica extract, and allium extract.
Description
본 발명은 식물의 새싹 또는 새순추출물을 함유한 피부 외용제 조성물에 관한 것으로, 구체적으로는 밀싹, 브로콜리, 유채, 콩싹, 잇꽃, 클로브 등의 새싹추출물과 회화나무 꽃봉오리, 자목련 꽃봉오리, 차나무 잎 등의 새순추출물을 유효성분으로 포함하는 피부 외용제 조성물에 관한 것이다.
The present invention relates to a composition for external application for skin containing a bud or an extract of a plant, and more particularly, to a composition for external application for skin comprising bud extract, broccoli, oilseed rape, sprout, safflower, clove and the like, As an active ingredient, to a composition for external application for skin.
피부는 신체의 전 표면을 덮고 있는 기관으로서, 외부의 환경 및 자극으로부터 인체를 보호하고, 체내의 수분증발을 억제하는 기능을 수행하고 있다. 따라서, 피부는 외부환경에 직접적으로 노출될 수밖에 없다.Skin is an organs covering the entire surface of the body. It protects the human body from the external environment and stimulation, and suppresses evaporation of water in the body. Therefore, the skin is exposed directly to the external environment.
이러한 피부를 구성하는 세포의 활성과 외부 감염원에 대한 피부 방어능은 오존층 파괴에 따라 지표에 도달하는 자외선 증가, 스트레스에 의한 면역력 약화 및 유해 화학 물질 등의 오염원에 대한 노출이 증가되면서 감소하게 된다. 이에 따라, 피부는 외부 자극에 민감하게 반응하게 되고, 홍반, 부종, 가려움증 등의 피부 트러블 및 염증 반응이 유발된다. 또한, 염증 반응 과정에서 생성되는 물질들이 부수적으로 피부의 색소 침착을 일으키고, 피부 탄력 섬유와 콜라겐 섬유의 붕괴를 촉진시켜 피부 주름의 증가에까지 영향을 미친다.The activity of the cells constituting the skin and the skin protecting ability against the external infectious diseases are decreased as the ozone layer destruction increases the ultraviolet rays reaching the surface, weakening the immunity due to stress, and exposure to pollution sources such as toxic chemicals. As a result, the skin is sensitive to external stimuli, and skin troubles such as erythema, edema, itching, and inflammatory reaction are induced. In addition, the substances produced during the inflammatory reaction cause skin pigmentation, skin elastic fibers and collagen fibers to collapse, thus affecting the increase of skin wrinkles.
생체 내에서 에너지 생산을 위한 산화 과정 중에 상당량의 활성산소종(reactive oxygen species: ROS)들이 생성된다. 이러한 활성산소종은 생체 내 제거기전에 의해 대부분 소멸되지만 순간적으로 활성산소종이 다량으로 발생되거나 만성적으로 활성산소종이 발생되어 항산화 방어계와의 균형이 깨지면 각종 질환의 원인이 된다.A significant amount of reactive oxygen species (ROS) are generated during the oxidation process for energy production in vivo. Most of these reactive oxygen species disappear by the in vivo eliminator, but when large amounts of active oxygen species are instantly generated or chronic active oxygen species are generated and the balance with the antioxidant defense system is broken, it becomes a cause of various diseases.
활성산소종에는 산소(oxygen,1O2), 과산화(superoxide, O2 -), 수산기라디칼(hydroxyl radical, OH), 과산화수소(hydrogen peroxide, H2O2) 등이 있는데, 이들은 피부 세포 및 조직의 손상은 물론이며 항산화 효소와 비효소적 항산화제로 구성된 산화제와 항산화제의 균형을 파괴하고 지질과산화, 단백질 산화, 콜라겐과 엘라스틴의 사슬절단 및 멜라닌 생성반응의 촉진, DNA의 산화와 같은 생체 구성 성분의 손상을 야기한다.Active oxygen species include oxygen (oxygen, 1 O 2), hydrogen peroxide (superoxide, O 2 -) There are, such as the hydroxyl radical (hydroxyl radical, OH), hydrogen peroxide (hydrogen peroxide, H 2 O 2 ), which skin cells and tissues , As well as destroying the balance of antioxidants composed of antioxidant enzymes and non-enzymatic antioxidants and destroying the balance of oxidants and antioxidants and promoting the production of lipid peroxidation, protein oxidation, chain cleavage of collagen and elastin and melanogenesis reaction, Lt; / RTI >
이에 따라 피부는 탄력감소, 주름살, 기미 및 주근깨 등의 피부 노화가 가속화된다. 따라서 피부노화를 지연시키고 억제하기 위해서는 생체 내 뿐만 아니라 피부에서의 과잉 활성산소종을 억제하고 또한 활성산소종을 효율적으로 제거할 수 있는 항산화제의 개발이 필요하다.As a result, skin aging of skin such as reduced elasticity, wrinkles, spots and freckles is accelerated. Therefore, in order to delay and inhibit skin aging, it is necessary to develop an antioxidant capable of inhibiting excess active oxygen species in the skin as well as in vivo and efficiently removing active oxygen species.
염증은 외부 자극에 대한 생체조직의 생리적인 방어반응의 하나로 임상적으로는 발적, 발열, 종창, 동통, 기능장애 등의 증상이 나타나는데 이는 해로운 주위환경, 즉 세균과 같은 외부 이물질의 침입과 기계적 손상으로부터 피부를 보호하려는 생리기전이다.Inflammation is one of physiological defense reactions of biological tissues to external stimuli. Clinically, symptoms such as fever, fever, swelling, pain, and dysfunction are observed. This is caused by intrusion of external foreign substances such as bacteria and mechanical damage To protect the skin from the physiological mechanism.
다양한 염증성 매개물질들은 산화제 생성을 활성화하여 조직 항산화 능력을 감소시키므로 조직의 기본적인 대사 구조적 인자에 대한 손상을 주어 독성을 유발하고, 이러한 다양한 세포와 조직에서의 산화작용은 독특한 산화물질을 생성하게 되며 복잡한 활성산소종의 이차적인 조직반응이 시작된다.Various inflammatory mediators activate oxidant production and reduce tissue antioxidant capacity, thus impairing the basic metabolic structural factors of the tissue and causing toxicity. Oxidation in these various cells and tissues produces a unique oxidant, A secondary tissue reaction of reactive oxygen species begins.
활성산소종과 활성질소종(reactive nitrogen species: RNS)은 생체 내 여러 가지 세포의 작용을 조절하는 염증반응과 같이 관련되어 있다. 염증의 경우 활성산소종에 의해 세포막의 지질이 과산화되고 단백질이 분해되면, 세포막의 구조를 유지하지 못하여 세포막의 칼슘이온 채널의 변화가 일어난다. 이러한 변화로 인해 세포내 칼슘 유입이 증가하면 칼슘이온의 촉매로 포스포리파아제 A2(PLA2)가 활성화 된다.Active oxygen species and reactive nitrogen species (RNS) are associated with inflammatory responses that regulate the action of various cells in vivo. In the case of inflammation, lipid peroxidation of the cell membrane by the active oxygen species and degradation of the protein can not maintain the cell membrane structure, resulting in a change in the calcium ion channel of the cell membrane. These changes lead to the activation of phospholipase A 2 (PLA 2 ) as a calcium ion catalyst as the intracellular Ca 2+ influx increases.
활성산소종은 비만세포에서 PLA2를 활성화시키는데 이것에 의해 생성된 아라키돈산은 시클로옥시게나제(cycloxygenase: COX)와 리폭시게나제(lipoxygenase)의 작용으로 염증매개물질인 프로스타그란딘과 류코트리엔을 생성시킨다.The active oxygen species activates PLA2 in mast cells, and the arachidonic acid produced by it produces the inflammatory mediators prostaglandins and leukotrienes by the action of cyclooxygenase (COX) and lipoxygenase.
따라서, 리폭시게나제와 시클로옥시게나제의 저해제는 염증매개물질의 생성을 억제할 뿐만 아니라 염증시 생성되는 활성산소종에 의한 세포막 파괴와 과산화반응을 억제하는 물질로서 항염증 작용을 나타낼 수 있다. 또한 과다 염증에 의해 생성되는 단백질 및 지질분해효소를 억제함으로써 그로 인해 손상되는 세포들을 보호하여 피부 노화를 억제할 수 있다.Therefore, the inhibitors of lipoxygenase and cyclooxygenase not only inhibit the production of inflammatory mediators but also inhibit cell membrane destruction and peroxidation by reactive oxygen species produced during inflammation, and may exhibit anti-inflammatory action. It also inhibits proteins and lipolytic enzymes that are produced by hyperinflammation, thereby protecting cells that are damaged thereby to inhibit skin aging.
삭제delete
본 출원의 발명자들은 심도 있는 연구와 다양한 실험들을 계속한 끝에, 밀싹, 브로콜리, 유채, 콩싹, 잇꽃, 클로브과 회화나무 꽃봉오리, 자목련 꽃봉오리, 차나무 잎으로부터 추출한 새싹추출물 및 새순추출물을 유효성분으로 포함하는 피부 조성물이 피부 재생과 증식을 촉진함으로써 피부 노화를 억제 내지 개선할 수 있다는 사실을 발견하고 본 발명을 완성하기에 이르렀다.
The inventors of the present application have continued to carry out in-depth research and various experiments, and have found that the active ingredient of the present invention is an extract of sprouts, broccoli, rapeseed, sprouts, safflower, clove and flower buds, sprout buds extracted from tea leaves, The present inventors have found that the skin composition of the present invention can inhibit or ameliorate skin aging by promoting skin regeneration and proliferation, and have completed the present invention.
본 발명은 상기의 목적을 달성하기 위해 아래와 같은 특징을 갖는다.The present invention has the following features in order to achieve the above object.
본 발명의 일실시예에 따른 피부 외용제 조성물은 유효성분으로서, 밀싹 새싹추출물, 브로콜리 새싹추출물, 유채 새싹추출물, 콩싹 새싹추출물, 잇꽃 새싹추출물 및 클로브 새싹추출물로 구성된 새싹추출물과, 회화나무 꽃봉오리 새순추출물, 자목련 꽃봉오리 새순추출물 및 차나무 잎 새순추출물로 구성된 새순추출물을 함유한다. The composition for external application for skin according to one embodiment of the present invention is characterized by comprising, as an active ingredient, a sprout extract comprising a bud sprout extract, a broccoli sprout extract, a rape bud sprout extract, a budrose sprout extract, a safflower sprout extract and a clover sprout extract, Extract, Seedlings of Seedlings and Seedlings of Tea Leaves.
여기서 상기 새싹추출물은 밀싹 새싹추출물, 브로콜리 새싹추출물, 유채 새싹추출물, 콩싹 새싹추출물, 잇꽃 새싹추출물 및 클로브 새싹추출물을 1~5 : 1~5 : 1~5 : 1~5 : 1~5 : 1~5의 중량비로 함유하며, 상기 새순추출물은 회화나무 꽃봉오리 새순추출물, 자목련 꽃봉오리 새순추출물 및 차나무 잎 새순추출물을 1~5 : 1~5 : 1~5의 중량비로 함유한다. Wherein the sprout extract is selected from the group consisting of 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 To 5% by weight of the extract. The extract contains the larvae of the flower buds, the larvae of the larvae and the extract of the tea leaf larvae at a weight ratio of 1: 5: 1 to 5: 1 to 5.
아울러 상기 피부 외용제 조성물은, 새싹추출물과 새순추출물이 1~2 : 1~2의 중량비로 함유되며, 상기 새싹추출물 및 새순추출물의 총 중량은 조성물 총 중량에 대하여 0.001 내지 10 중량%로 포함된다. The composition for external application for skin according to the present invention contains the sprout extract and the sprout extract at a weight ratio of 1: 2: 1 to 2, and the total weight of the sprout extract and the sprout extract is 0.001 to 10% by weight based on the total weight of the composition.
또한 상기 새싹추출물 및 새순추출물은 열수, C1 -4의 저급 알코올 또는 이들의 혼합 용매에 온침으로 추출, 여과하고 감압 농축하여 제조되며, 상기 피부 외용제 조성물은 유연화장수, 영양화장수, 마사지크림, 영양크림, 팩, 젤 또는 피부 점착타입 화장료의 제형이거나, 로션, 연고, 겔, 크림, 패취 또는 분무제인 것이 바람직하다. The extracts of the buds and the extracts of the sprouts are prepared by hot extraction, filtration and concentration under reduced pressure of hydrothermal, C 1 -4 lower alcohol or a mixed solvent thereof, and the composition for external application for skin is selected from the group consisting of softening longevity, Cream, pack, gel or skin adhesive type cosmetic, or a lotion, ointment, gel, cream, patch or spray.
또한 상기 피부 외용 조성물은 알로에 잎 추출물, 병풀 추출물 및 연교 추출물 중 선택되는 어느 하나 이상을 더 함유한다.
The composition for external use on the skin may further contain at least one selected from the group consisting of aloe leaf extract, centilla sp.
본 발명에 따른 새싹추출물 및 새순추출물을 포함한 조성물은, 피부 표피 줄기세포의 활성을 증진시키고, 피부세포의 증식을 촉진할 뿐만 아니라, 항산화력을 높이는 효과가 있으며, 이를 통해 건강한 피부 관리가 가능해지는 효과가 있다.
The composition of the present invention comprising a bud extract and a sprout extract according to the present invention has an effect of enhancing the activity of skin epidermal stem cells and promoting the proliferation of skin cells as well as enhancing the antioxidant ability, It is effective.
도 1은 무모생쥐를 이용한 광노화 동물모델에서 6종의 새싹 추출물 및 3종의 새순 추출물의 혼합물이 자외선에 의한 콜라겐 분해를 억제하여 피부 내 콜라겐 양을 증진시킨 것을 나타내는 그래프이다.FIG. 1 is a graph showing that a mixture of 6 sprout extracts and 3 sprout extracts in a photoperiod animal model using hairless mice inhibited collagen degradation by ultraviolet rays to increase the amount of collagen in skin.
따라서, 본 발명에 따른 조성물은, 밀싹 새싹추출물, 브로콜리 새싹추출물, 유채 새싹추출물, 콩싹 새싹추출물, 잇꽃 새싹추출물 및 클로브 새싹추출물로 구성된 새싹추출물과, 회화나무 꽃봉오리 새순추출물, 자목련 꽃봉오리 새순추출물 및 차나무 잎 새순추출물로 구성된 새순추출물을 유효성분으로 포함하고 있다.Therefore, the composition according to the present invention can be used as an extract of buds, a bud sprout extract, a broccoli sprout extract, a rape bud sprout extract, a bud sprout extract, a safflower sprout extract and a clover sprout extract, And tea leaf extract. It contains as an active ingredient.
일반적으로, 새싹은 식물의 줄기 세포라고 할 수 있다. 식물은 동물과 달리 식물체 전체가 줄기 세포가 될 수 있는 가능성을 가지고 있다. 이는 식물체가 조직만을 가지고 있고 기관으로까지 분화되어 있지 않기 때문이다. 식물의 대표적인 성체 줄기 세포는 뿌리나 줄기 끝의 생장점에 있는 세포이고, 씨앗 등은 동물의 배아줄기 세포에 대응된다고 할 수 있다. 따라서, 뿌리, 줄기 혹은 잎 부분도 일정한 조건에서 끊임없이 분열하는 줄기 세포가 될 수 있으며, 특히 새싹에는 성장에 필요한 다양한 물질들이 풍부하게 포함되어 있다.Generally, a bud is a stem cell of a plant. Unlike animals, plants have the potential to make whole plants become stem cells. This is because the plant has only the tissue and is not differentiated into the organ. A representative adult stem cell of a plant is a cell in the growth point of a root or stem end, and a seed etc. corresponds to an embryonic stem cell of an animal. Therefore, stem, stem or leaf part can be a constantly dividing stem cell under certain condition, and buds in particular contain abundant variety of substances necessary for growth.
따라서, 본 발명에서는 피부 표피 줄기 세포를 활성화하고 피부세포의 성장을 촉진할 뿐만 아니라, 피부재생과 피부노화 지연에 영향을 주는 각종 성장인자들의 발현을 증가시키는 효능이 뛰어난 새싹 추출물을 함유하는 조성물을 제공한다.Accordingly, the present invention provides a composition containing a sprout extract having an excellent effect of activating skin epidermal stem cells and promoting the growth of skin cells as well as increasing the expression of various growth factors affecting skin regeneration and skin aging delay. to provide.
본 발명에 따른 조성물에 유효성분으로 함유되는 6종의 새싹과 3종의 새순에 대하여 구체적으로 살펴보면 다음과 같다.The six sprouts and three sprouts contained as an active ingredient in the composition according to the present invention will now be described in detail.
먼저, 밀(Triticum vulgare)은 외떡잎식물 벼목 화본과의 한해살이풀로서, 높이 1m 정도이고 2~3대가 같이 나와서 자라며 밋밋하고 마디가 길다. 5월에 꽃이 피고 6~7월에 열매가 성숙되고 영과(穎果)는 넓은 타원체이며 갈색이고 영(穎)에서 잘 떨어진다. 열매성분으로는 녹말 53~70%, 단백질 11% 안팎, 당분(자당, 포도당 등) 2~7%, 텍스트린 2~10%, 기름 1.6% 안팎, 시토스테롤, 레시틴, 알란토인 등을 함유한다. 밀눈에는 토코페놀이 함유되어 있어서 피부노화를 방지하고 피부를 탄력있게 해준다. 또한 식은땀, 골증허열, 소화약으로도 쓰인다.Firstly, wheat (Triticum vulgare) is a year-old seedling of the almond leaf plant lanceolate. It grows about 1m in height and 2 ~ 3 generations together. It is plain and has long nodes. Flowers bloom in May, fruit matures in June and July, and the spirit and crown are wide ellipsoid, brown and fall well in the ying. The fruit ingredient contains 53 ~ 70% of starch, 11 ~ 11% of protein, 2 ~ 7% of sugar (sucrose and glucose), 2 ~ 10% of texturin, 1.6% of oil and it contains citrate, lecithin and allantoin. It contains tocopherol to prevent skin aging and make skin elastic. It is also used for sweating, osteoporosis, and digestion.
본 발명에서 밀의 새싹인 밀싹을 사용한다. 새싹은 발아한지 5 내지 10일 정도된 것으로, 새싹은 발아하면서 외부의 유해환경으로부터 자신을 방어할 무기로서 신물질을 합성하는데, 씨앗 상태에서 없었던 각종 효소, 비타민, 아미노산 등의 유용물질을 함유한다.In the present invention, wheat, a bud of wheat, is used. Sprouts are germinated for about 5 to 10 days. Sprouts are germinated and synthesize new materials as weapons to defend themselves from the harmful environment outside. They contain useful substances such as various enzymes, vitamins and amino acids that were not in the seed state.
발아 브로콜리(Brassica oleracea var . italica)는 설포라팬이라는 항암물질을 다량 함유하고 있어서 암예방과 암세포를 억제하는데 효과가 있다고 알려져 있다. 그외에도 베타카로틴, 비타민B, C 등을 함유하고 있다.Germinated broccoli ( Brassica oleracea there is . italica ) contains a large amount of anti-cancer substances called sulfolafan and is known to be effective in preventing cancer and suppressing cancer cells. In addition, it contains beta carotene, vitamin B, C and so on.
본 발명에 사용되는 상기 유채(학명: Brassica campestris subsp. napus var. nippo-oleifera)는 쌍떡잎식물이며 양귀비목 겨자과의 두해살이풀이다. 상기 유채는 평지라고도 하며 보통종(Brassica napus)과 서양종(B. campestris)이 있다.The rapeseed (Brassica campestris subsp. Napus var. Nippo-oleifera) used in the present invention is a dicotyledonous plant and is a biennial plant of a poppy bark. The rapeseed is also called plains, and is usually of the species Brassica napus and B. campestris.
상기 보통종은 지중해 연안에서 중앙아시아 고원 지대 원산으로서, 꽃은 노란색이고 종자는 붉은 갈색이라서 적종(赤種)이라고도 하며, 상기 서양종은 스칸디나비아반도에서 시베리아와 카프카스 지방에 걸친 지역이 원산지로서, 꽃은 녹색을 띤 붉은색이며 종자는 검은빛을 띤 갈색이다. 한국에서 재배하는 것은 서양종이며, 1962 년부터 유료작물(油料作物)로서 본격적으로 재배하였다. 상기 유채는 높이가 80∼130 ㎝이며, 표면은 매끄럽고 녹색이다. 원줄기에서는 15 개 안팎의 1차 곁가지가 나오고, 이 가지에서 다시 2∼4 개의 2차 곁가지가 나온다. 잎은 바소꼴이고 끝이 둔하고, 아래쪽 줄기에 달린 잎은 긴 잎자루가 있으며 잎 가장자리는 깊게 갈라지며, 위쪽 줄기에 달린 잎은 잎자루가 없으며 줄기를 둘러싸고 그 끝은 가늘다.The common species is native to the Central Asian highlands from the Mediterranean coast, flowers are yellow and seeds are reddish brown, so they are also called red species. The Western species originate in the Scandinavian peninsula from Siberia to the Caucasus region, It is greenish red and the seed is blackish brown. It is a western species cultivated in Korea. Since 1962, it has been cultivated as a paying crop (oil product) in earnest. The rape has a height of 80 to 130 cm, and the surface is smooth and green. In the main stem, there are about 15 primary branches and two to four secondary branch branches. Leaves are basal and end is dull. Leaves on lower stem have long petiole. Leaf edge is deeply cracked. Leaf on upper stem has no petiole, it surrounds stem and its tip is thin.
서양종의 잎은 두껍고 혁질(革質: 가죽같은 질감)이며, 보통종은 연한 녹색이고 잎살이 비혁질이다. 줄기에는 보통 30∼50 개의 잎이 붙는다. 꽃은 3∼4 월에 총상꽃차례로 피며 가지 끝에 달리며, 배추꽃과 비슷하며 약 10 ㎝ 길이의 꽃자루를 가진 홑꽃이 핀다. 꽃잎, 꽃받침은 각각 4 개로 갈라지며 수술 6 개, 암술 1 개, 4 개의 꿀샘이 있다. 성숙한 이삭 길이는 가지의 위치, 재식방법, 품종 등에 따라 다르나, 대개 35∼45 ㎝이고 한 이삭에 30∼40 개의 열매가 달린다. 열매는 각과(角果)로서 길이 8 ㎝ 가량의 원통 모양이다. 중앙에는 봉합선이 있으며 완숙하면 봉합선이 갈라져서 종자가 떨어진다.Leaves of western varieties are thick and swollen (leather: leather-like texture), and the species is light green and the leaves are undrained. The stem usually has 30 to 50 leaves. The flowers bloom in April ~ April, bloom on the end of the branches, similar to the Chinese cabbage, and one flower with a peduncle about 10 cm long. Petal and calyx are divided into 4 pieces each, and there are 6 stamens, 1 pistil and 4 honey glands. The length of mature ears varies depending on the location of the branches, the method of planting, the variety, etc., but it is usually 35 to 45 ㎝, with 30 to 40 fruits per ears. The fruit is angular and has a cylindrical shape with a length of about 8 ㎝. In the center there is a suture line, and when ripe, the suture line is split and the seed falls.
속은 2실로 되고 투명한 격막으로 갈라지며, 보통 20 개 가량의 짙은 갈색 종자가 들어 있다. 번식은 종자로 하며, 품종에는 파성(播性)의 정도에 차이가 있는데, 한국에서 재배하는 서양종은 맥류와는 달리 감광성이 약하고 감온성의 차이에 의해서 파성 정도가 달라진다. 수확량이 많고 품질이 좋으며 빨리 자라고 추위와 습기에 잘 견디는 것이 우량품종으로, 대표적인 품종은 아사히, 유달, 목포11호, 용당 등이다. 종자에는 38∼45 %의 기름이 들어 있는데, 15∼20 %의 가용성 질소질과 20 % 가량의 단백질이 들어 있는 식용유로서 콩기름 다음으로 많이 소비하고 있으며, 깻묵은 사료나 비료로 쓴다. The genus is divided into 2 chambers and is divided into a transparent diaphragm, usually containing about 20 dark brown seeds. Breeding is a seed, and there is a difference in the degree of seeding in varieties. In contrast, in western varieties cultivated in Korea, the sensitivity to light is weak and the degree of variability depends on the difference in temperature sensitivity. It is a good variety with high yield, good quality, fast growing and good resistance to cold and moisture. Representative varieties are Asahi, Yudal, Mokpo 11 and Yongdang. Seeds contain 38 to 45% of oil, 15 to 20% of soluble nitrogen and 20% of the protein contains cooking oil as the next most consumption of soybean oil is used as feed or fertilizer.
꽃은 밀원식물(蜜源植物)이고, 종자에서 분리한 지방유를 연고기제(軟膏基劑), 유성주사약(油性注射藥)의 용제나 기계의 윤활유로 사용하며, 한국(제주도와 남부지방), 일본, 중국 등지에 분포한다.The flower is a herbaceous plant, and the fatty oil separated from the seed is used as a lubricant for the ointment base, oily injection oil, and machine, and is used in Korea (Jeju and South), Japan , And China.
아울러 콩싹은 콩이 발아된 것을 말하며 콩을 음지가 아니라, 양지에서 발아시킬 경우, 광합성을 통하여, 콩에 존재하지 않는 영양소가 부가된 콩싹을 제조할 수 있ㄷ다. In addition, the bud refers to the germination of soybeans. When the soybeans are germinated in sunshine instead of in the shade, photosynthesis can produce beans with nutrient additions that are not present in the soybeans.
양지에서 제조된 콩싹은 음지에서 발아시킨 콩나물보다 크기가 작고, 잎이 무성하며, 줄기가 뻣뻣하고 질겨서, 식용하기에 적합하지 않아, 식재료로서는 외면받고 있는 실정이다.The bean sprouts produced in sunny area are smaller than bean sprouts germinated in shade, the leaves are silky, the stems are stiff and stiff, and are not suitable for edible use.
본 발명에서는 양지에서 충분한 습기를 공급하며, 대두를 발아시킨 결과, 1일만에 콩싹을 얻을 수 있었으나, 크기가 작고, 영양소가 충분하게 보충되지 못하였기 때문에, 적절한 크기와 영양소를 함유하는 콩싹을 수득할 수 있는 발아기간을 선정한 결과, 약 5 내지 7일 정도의 기간으로 발아시키는 것이 바람직하다. In the present invention, sufficient moisture was supplied from the sunny place and the soybean was germinated. As a result, the beans could be obtained in only one day. However, since the size was small and the nutrients were not sufficiently replenished, the beans containing the proper size and nutrients were obtained As a result of selecting the period of germination, it is preferable to germinate at a period of about 5 to 7 days.
그 이유는, 5일 미만의 기간동안 발아시킨 경우에는, 영양소의 함량이 현저하게 낮고, 7일을 초과하여 발아시킨 경우에는, 콩싹에 함유된 섬유소로 인하여, 목적하는 추출물에 적합하지 않게 된다. The reason for this is that when germinated for less than 5 days, the content of nutrients is remarkably low, and when germinated for more than 7 days, the fiber contained in the sprouts is not suitable for the desired extract.
또한, 본 발명에서는 콩싹을 추출하는 방법으로 열수, C1 -4의 저급 알코올 또는 이들의 혼합 용매에 온침으로 추출, 여과하고 감압 농축하여 추출물을 수득한다.Further, in the present invention, hot water, C 1 -4 lower alcohol or a mixed solvent thereof is extracted with warming, filtered, and concentrated under reduced pressure to obtain an extract.
아울러 잇꽃(safflower, Carthamus tinctorius L.)은 흔히 홍화라고도 하며, 국화과(Compoitae)에 속하는 1년생 초본으로서, 한방에서는 잇꽃을 파골, 골다공증, 골형성부전 등의 골질환의 치료제와 이뇨제로서 이용하여 왔다.In addition, safflower (Carthamus tinctorius L.) is also known as safflower and is a one-year-old herb belonging to the Asteraceae family (Compoitae), and has been used as a diuretic for treating bone diseases such as osteoporosis, osteoporosis, .
이러한, 잇꽃의 골질환 치료 효과가 의학적으로 입증됨에 따라, 최근에 들어 잇꽃의 생산량이 크게 증가하고 있는 실정이다. 최근의 연구결과에 의하면, 잇꽃은 항산화 효과가 뛰어난 세로토닌(serotonin)화합물, 플라보노이드(flavonoid) 성분인 아카세틴(acacetin) 및 뼈 질환에 효과가 있는 리그난(lignan) 화합물을 함유하고 있으며, 이러한 잇꽃의 분말은 골질환의 치료효과 뿐만 아니라 지질대사를 개선시키는 효과도 나타냄이 보고되었다. As a result of medically proving the therapeutic effect of the sickle bones disease, the production of safflower has greatly increased recently. Recent research has shown that safflower contains serotonin compounds with excellent antioxidant activity, acacetin as a flavonoid ingredient and lignan compounds as effective against bone diseases. It has been reported that the powder not only improves the therapeutic effect of bone diseases but also improves lipid metabolism.
아울러 클로브는 학명이 에우게니아 카리오필리에이트(Eugenia caryophyliate)이고, 리날린 아세테이트(Linalylacetate), 리날룰(Linalool) 및 유지놀(Eugenol)을 주 구성성분으로 하며, 항경련, 항우울 및 강한 신경계 진정효과 등이 있는 것으로 알려져 있다.Clove is also known as Eugenia caryophyliate, whose main constituent is linalylacetate, Linalool and Eugenol, and has anti-convulsant, antidepressant and strong nervous system Soothing effects and so on.
또한 회화나무(Sophora japonica L.)는 콩과식물에 속하는 활엽교목으로 우리나라, 중국, 일본 등지에 널리 분포한다. 회화나무는 수피가 회색이거나 짙은 회색을 띄고 내수피는 황색으로 특이한 냄새가 나며, 잎은 호생한다. 회화나무 꽃은 주로 7∼8월에 피우며, 이 시기의 꽃을 한방에서는 괴화(槐花)라 하고 꽃봉오리는 괴미(槐米)라 하여 약용으로 사용한다. In addition, Sophora japonica L. is a broad-leaved arboreous tree belonging to legume plants and widely distributed in Korea, China, and Japan. Painted trees have gray or dark gray barks, and yellowish-green blooms have a peculiar smell. Painted tree flowers bloom mainly in July-August, and the flowers of this period are called 槐花 (槐花) in one shot, and the buds are called 미米 (槐米).
그 외에도 지혈, 토혈, 변혈 등에 이용되며, 혈압강하작용과 항염효과도 있는 것으로 알려져 있다. 민간에서는 회화나무 잎을 삶은 물로 치질(痔疾)부위를 수세하고 생(生) 또는 초(炒)괴화를 비(鼻)출혈, 세균성 치질의 치유에, 고혈압 환자가 상복하여 중풍의 예방에 사용하여 왔다(한국자연의약연구회, 1985).In addition, it is used for hemostasis, hematemesis, blood flow, and is known to have hypotensive effect and anti-inflammatory effect. In the private sector, boiled water is used to wash the hemorrhoids, and raw or fried calves are used for nasal bleeding, bacterial hemorrhoid healing, hypertensive patients to prevent paralysis (Korea Natural Medicine Research Association, 1985).
지금까지 회화나무 줄기인 목부에서 이소플라본(isoflavones)과 그 배당체인 Biochain A-7-D-gentiobioside, sissotrin 및 pratensein이 분리되었다는 보고가 있다(Takeda 등, 1977).It has been reported that isoflavones and their glycosides Biochain A-7-D-gentiobioside, sissotrin and pratensein have been isolated from the tree trunk (Takeda et al., 1977).
중국에서 들어온 귀화식물이다. 관목상인 것이 많으며 관상용으로 심는다. 높이 15m에 달하고 가지가 많이 갈라진다. 잎은 마주나고 달걀을 거꾸로 세운 듯한 모양이며 가장자리가 밋밋하다. 양면에 털이 있으나 점차 없어지고 잎자루는 길이 7∼15mm이다. It is a naturalized plant that came in from China. Many shrubs are planted for ornamental purposes. It reaches 15m in height and branches are split a lot. Leaves are opposite to each other and look like inverted eggs with flat edges. There are hairs on both sides but gradually disappear, and petiole length is 7 ~ 15mm.
꽃은 4월에 잎보다 먼저 피고 검은 자주색이다. 꽃받침조각은 녹색이며 3개이다. 꽃잎은 6개이고 길이 10cm 내외이며 햇빛을 충분히 받았을 때 활짝 핀다. 꽃잎의 겉은 짙은 자주색이며 안쪽은 연한 자주색이다. 수술과 암술은 많다. Flowers bloom earlier than leaves in April, and are black purple. Calyx is green and has three pieces. It has 6 petals, 10cm long and it blooms when it is fully sunlight. The petals are dark purple on the outside and light purple on the inside. There are many operations and pistils.
열매는 달걀 모양 타원형으로 많은 골돌과로 되고 10월에 갈색으로 익으며 빨간 종자가 실에 매달린다. 꽃잎의 겉면이 연한 홍색빛을 띤 자주색이고 안쪽이 흰색인 것을 자주목련(M. denudata var. purpurascens)이라고 한다.The fruit is egg-shaped oval, and it turns into a lot of corolla. It ripens brown in October, and the red seed hangs on the thread. M. denudata var. Purpurascens is often referred to as petals whose surface is light purplish reddish purple and white inside.
마지막으로 차(茶)나무는 차나무과(茶-科)에 속하는 상록 소교목으로, 키가 10m가지 자라지만 재배하기 쉽게 가치를 치기 때문에 보통 1m정도 자라며, 많은 가지가 나온다.Finally, the tea tree is an evergreen small arboreous tree belonging to the tea family. It grows about 10m tall but grows easily. It usually grows about 1m and there are many branches.
타원형 잎은 가장자리에 둔한 톱니가 있으며, 끝과 기부는 모두 뾰족하고, 꽃은 10~11월 경 잎겨드랑이 또는 가지 끝에 1~3송이씩 흰색 또는 연한 분홍색으로 핀다. 열매는 둥글고 모가진 형태이다.The elliptical leaves have dull sawtooth on the edge. Both ends and base are pointed, and the flowers bloom in white or light pink, 1 ~ 3 on the leaf axil or end of the branch from October to November. The fruit is round and has a round shape.
상기와 같은 차나무는 어린잎을 따거 찌거나 열을 가해 효소의 작용을 억제시켜 말린 녹차(綠茶) 또는 엽차로 복용한다.The above-mentioned tea leaves are used as dried green tea or green tea by depressing the action of the enzyme by stinging or heating the young leaves.
상기 차나무의 잎(이하 녹차잎이라 한다)에는 카페인, 탄닌, 카테킨(catechin), 비타민, 아미노산, 질소화합물, 엽록소, 탄수화물, 유기산, 무기염류 등이 들어있어 전세계에 걸쳐 기호품으로 널리 복용되며, 또한 녹차에 함유된 카페인은 강심작용, 근육수축작용, 피로회복, 이뇨작용, 각성작용을 하며, 타닌에 의해 중금속이나 알칼로이드와 같은 독극물 및 단백질의 침전작용을 하므로 해독효과가 있고, 비타민에 의해 신진대사를 촉진시키며 심장, 혈관, 위장 등의 정상적 기능을 유지하는 역할을 한다.The leaves of the tea tree (hereinafter referred to as green tea leaves) are widely used as a precious ingredient all over the world because they contain caffeine, tannin, catechin, vitamins, amino acids, nitrogen compounds, chlorophyll, carbohydrates, organic acids, Caffeine contained in green tea has a detoxifying effect because it acts on precipitation of toxic substances such as heavy metals and alkaloids and proteins by tannins and acts on the metabolism by vitamins And plays a role in maintaining normal functions such as heart, blood vessel, and stomach.
또한 차나무에 함유된 불소는 치아 표면을 코팅하여 산으로부터 치아를 보호하고, 충치의 원인이 되는 충치 세균의 발육을 억제시키며, 치석형성의 원인이 되는 GTase의 활성을 억제시키는 작용을 하며, 혈관 벽에서 콜레스테롤을 취하여 간에 회수함으로써 인체에 좋은 작용을 하는 HDL-콜레스테롤은 상승시키는데 비해 몸에 해로운 작용을 하는 LDL-콜레스테롤은 감소시키는 선택적 감소작용을 나타내는 작용을 하기도 한다.In addition, fluoride contained in tea plants protect teeth from acid by coating the surface of teeth, inhibits development of tooth decay bacteria causing tooth decay, inhibits the activity of GTase, which is a cause of tartar formation, Cholesterol in the liver by taking the recovery of the body works good for HDL-cholesterol, while the body is harmful to the body that acts to reduce the LDL-cholesterol also acts as a selective reduction action.
또한 술을 많이 마실 경우에 차를 함께 마시면 차에 함유된 여러 가지 성분에 의해 숙취가 빨리 해소되어지는데, 그 이유는 차나무 중에 들어 있는 카페인과 비타민 C, 아스파라긴산과 알라닌이라는 아미노산에 의해 알콜분해효소의 작용을 돕게되므로 알코올의 분해가 빨라지고, 카페인의 이뇨작용으로 알코올이 빨리 배설되기 때문으로 알려져 있다.In addition, if you drink a lot of alcohol when you drink tea together with the various ingredients contained in the tea hangover is quickly resolved because the caffeine in the vitamin C, asparaginic acid and alanine amino acids by the alcoholic enzymes And it is known that the alcohol is rapidly excreted by the diuretic action of caffeine.
본 발명에 따른 새싹 추출물을 수득하는 방법에는, 특별한 제한은 없으며, 바람직하게는 해당 나무의 싹으로부터 얻는 방법 또는 해당 씨앗을 발아시켜 얻는 방법 등이 사용될 수 있다.The method for obtaining the bud extract according to the present invention is not particularly limited, and preferably a method obtained from the bud of the tree or a method obtained by germinating the seed can be used.
상기의 방법으로 준비된 새싹 및 새순들을, 그대로 또는 분쇄하여 용매를 통해 추출함으로써 필요한 추출물을 수득할 수 있다. 이때 사용하는 용매는 식물로부터 당해 식물의 성분을 추출할 때 일반적으로 사용되는 용매를 선택할 수 있으며 특별히 한정되지 않는다. The buds and larvae prepared by the above method can be directly or pulverized and extracted through a solvent to obtain the required extract. The solvent used here is not particularly limited and can be selected from commonly used solvents for extracting the components of the plant from the plant.
사용되는 용매로는, 예를 들면, 열수 또는 물; 메탄올, 에탄올, 이소프로필 알콜, n-부탄올 등의 저급 알콜; 프로필렌 글리콜, 1,3-부틸렌 글리콜 등의 다가 알콜; 이들 알콜류의 함수물: n-헥산, 톨루엔 등의 탄화수소계 용매 등을 들 수 있지만 메탄올이나 에탄올 등의 저급 알콜을 추출 용매로서 사용하는 것이 바람직하다. As the solvent to be used, for example, hot water or water; Lower alcohols such as methanol, ethanol, isopropyl alcohol and n-butanol; Polyhydric alcohols such as propylene glycol and 1,3-butylene glycol; Hydroformates of these alcohols: hydrocarbons such as n-hexane and toluene, and the like, but lower alcohol such as methanol or ethanol is preferably used as the extraction solvent.
상기 저급 알콜을 추출 용매로 사용하는 경우에는, 수득되는 추출물을 그대로 본 발명에 따른 조성물에 배합할 수 있지만, 추출 용매를 증류 제거한 다음 필요에 따라 건조 후 배합할 수 있다. When the lower alcohol is used as an extraction solvent, the obtained extract may be directly incorporated into the composition according to the present invention, but the extraction solvent may be distilled off and then dried and blended as necessary.
본 발명에 따른 하나의 실시예에서, 상기 새싹 추출물 및 새순 추출물을 함유하는 조성물은, 시험관 실험 및 생체(in vivo) 실험을 근거로 볼 때, 조성물 총 중량에 대하여 0.001 내지 10 중량%, 바람직하게는 0.01 내지 5 중량%의 양으로 함유될 수 있다.In one embodiment according to the present invention, the composition containing the bud extract and the larval extract is used in an amount of 0.001 to 10% by weight, preferably 0.001 to 10% by weight, based on the total weight of the composition, based on in vitro test and in vivo experiment May be contained in an amount of 0.01 to 5% by weight.
또한, 본 발명에 따른 조성물은 다양한 형태의 제형으로 제조될 수 있다.In addition, the compositions according to the present invention may be prepared in various forms of formulation.
하나의 실시예에서, 본 발명에 따른 조성물은 경구 투여용 조성물일 수 있다. 또한, 본 발명에 따른 조성물은 화장료 조성물, 건강식품 조성물 또는 의약 조성물일 수 있다. In one embodiment, the composition according to the present invention may be a composition for oral administration. In addition, the composition according to the present invention may be a cosmetic composition, a health food composition or a pharmaceutical composition.
하나의 실시예에서, 본 발명에 따른 조성물은 유연화장수, 영양화장수, 마사지크림, 영양크림, 팩, 젤 또는 피부 점착타입 화장료의 제형을 갖는 화장료 조성물일 수 있다. In one embodiment, the composition according to the present invention may be a cosmetic composition having a formulation of a softening agent, a nutritional lotion, a massage cream, a nutritional cream, a pack, a gel or a skin adhesive type cosmetic.
또 다른 하나의 바람직한 실시예에서, 상기 조성물은 로션, 연고, 겔, 크림, 패취 또는 분무제와 같은 경피 투여형의 제형으로 제조될 수 있다. In another preferred embodiment, the composition may be formulated into a transdermal dosage form such as a lotion, ointment, gel, cream, patch or spray.
상기 다양한 제형의 조성물에 있어서, 상기한 필수 구성성분 이외에도 당해 기술 분야의 통상의 지식을 가진 자의 기술 수준에 비추어 특별한 제한 없이 외용제의 제형 또는 사용 목적 등에 따라 다양한 물질들을 선정하여 배합할 수 있다.In the composition of the various formulations, various substances may be selected and compounded according to the formulation or use purpose of the external preparation without any particular limitation in view of the technical skill of those skilled in the art, in addition to the essential constituents described above.
본 발명에 따른 조성물을 의약품에 적용할 경우에는, 상기 추출물을 유효성분으로 하여 상용되는 무기 또는 유기의 담체를 가하여 고체, 반고체 또는 액상의 형태로 경구 투여제 혹은 비경구 투여제로 제제화 할 수 있다.When the composition according to the present invention is applied to a pharmaceutical product, the extract can be formulated into an oral or parenteral dosage form in the form of solid, semi-solid or liquid by adding a commercially available inorganic or organic carrier as an active ingredient.
상기 경구 투여를 위한 제재로서는 정제 (錠劑), 환제 (丸劑), 과립제 (顆粒劑), 연경 캡슐제, 산제, 세립제, 분제, 유탁제 (乳濁濟), 시럽제, 펠렛제 등을 들 수 있다. 또한, 상기 비경구 투여를 위한 제재로는 주사제, 점적제, 연고, 로션, 스프레이, 현탁제, 유제, 좌제 (坐劑) 등을 들 수 있다. 본 발명의 유효성분을 제제화하기 위해서는 상법에 따라서 실시하면 용이하게 제제화할 수 있으며 계면활성제, 부형제, 착색료, 향신료, 보존료, 안정제, 완충제, 현탁제, 기타 상용하는 보조제를 적당히 사용할 수 있다.Examples of the agent for oral administration include tablets, pills, granules, soft capsules, powders, granules, powders, emulsions, syrups and pellets. have. Examples of the parenteral administration agent include injections, drops, ointments, lotions, sprays, suspensions, emulsions, suppositories, and the like. In order to formulate the active ingredient of the present invention, it can be easily formulated according to the conventional method. Surfactants, excipients, coloring agents, spices, preservatives, stabilizers, buffering agents, suspending agents and other adjuvants can be suitably used.
본 발명에 따른 상기 약학 조성물은 경구, 비경구, 직장, 국소, 경피, 정맥 내, 근육 내, 복강 내, 피하 등으로 투여될 수 있다. The pharmaceutical composition according to the present invention may be administered orally, parenterally, rectally, topically, transdermally, intravenously, intramuscularly, intraperitoneally, subcutaneously and the like.
또한, 상기 유효성분의 투여량은 치료받을 대상의 연령, 성별, 체중과, 치료할 특정 질환 또는 병리 상태, 질환 또는 병리 상태의 심각도, 투여경로 및 처방자의 판단에 따라 달라질 것이다. 이러한 인자에 기초한 투여량 결정은 당업자의 수준 내에 있으며, 일반적으로 투여량은 0.001mg/kg/일 내지 대략 2000mg/kg/일의 범위이다. 더 바람직한 투여량은 0.5mg/kg/일 내지 2.5mg/kg/일이다. In addition, the dosage of the active ingredient will vary depending on the age, sex, and weight of the subject to be treated, the specific disease or condition to be treated, the severity of the disease or condition, the route of administration, and the judgment of the prescriber. Dosage determinations based on these factors are within the level of ordinary skill in the art and generally the dosage ranges from 0.001 mg / kg / day to approximately 2000 mg / kg / day. A more preferred dosage is 0.5 mg / kg / day to 2.5 mg / kg / day.
본 발명은 또한, 상기 추출물을 포함하는 기능성 식품 또는 식품첨가제를 제공한다. 오배자 발효물을 포함하는 조성물을 포함하는 발효유, 치즈, 요구르트, 주스, 생균제제 및 건강보조식품 등으로 가공될 수 있으며, 그 외 다양한 식품첨가제의 형태로 사용될 수 있다. 상기 추출물을 포함하는 기능성 식품 또는 식품첨가제는, 피부상태의 개선, 염증의 억제, 항산화 및 항노화 등의 다양한 효능을 나타낼 수 있다. The present invention also provides a functional food or food additive comprising the above extract. Cheese, yogurt, juice, probiotics, and health supplements containing the composition including the fermented product of the obovate, and may be used in the form of various other food additives. The functional food or food additive containing the extract may exhibit various effects such as improvement of skin condition, inhibition of inflammation, antioxidation and anti-aging.
일실시예에서 상기 조성물은, 본 발명이 목적으로 하는 주 효과를 손상시키지 않는 범위 내에서 주 효과에 상승 효과를 줄 수 있는 다른 성분 등을 함유할 수 있다. 예를 들어, 물성 개선을 위하여 향료, 색소, 살균제, 산화방지제, 방부제, 보습제, 점증제, 무기염류, 유화제 및 합성 고분자 물질 등의 첨가제를 더 포함할 수 있다. 그 외에도, 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당 및 해초 엑기스 등의 보조 성분을 더 포함할 수도 있다. 상기 성분들은 제형 또는 사용 목적에 따라서 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 그 첨가량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 선택될 수 있다. In one embodiment, the composition may contain other ingredients or the like that can give synergistic effects to the main effect within a range that does not impair the intended main effect of the present invention. For example, additives such as perfume, coloring agent, bactericide, antioxidant, preservative, moisturizing agent, thickening agent, inorganic salt, emulsifier and synthetic polymer substance may be further added for improvement of physical properties. In addition, it may further contain auxiliary components such as water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymeric polysaccharides and seaweed extract. The above components may be mixed and selected without difficulty by those skilled in the art depending on the purpose of formulation or use, and the amount thereof may be selected within a range that does not impair the objects and effects of the present invention.
예를 들어, 상기 성분들의 첨가량은, 조성물 전체 중량을 기준으로, 0.01~5 중량%, 보다 구체적으로는 0.01~3 중량% 범위일 수 있다.For example, the addition amount of the above components may be in the range of 0.01 to 5% by weight, more specifically 0.01 to 3% by weight, based on the total weight of the composition.
또한, 본 발명에 따른 조성물의 제형 역시 용액, 유화물, 점성형 혼합물, 타블렛, 분말 등의 다양한 형태일 수 있으며, 이는 단순 음용, 주사 투여, 스프레이 방식 또는 스퀴즈 방식 등의 다양한 방법으로 투여될 수 있다.In addition, the composition of the present invention may be in various forms such as solution, emulsion, viscous mixture, tablet, powder and the like, and may be administered by various methods such as simple drinking, injection, spraying or squeezing .
이하, 실시예 및 실험예 등을 통해 본 발명을 더욱 상술하지만, 하기 실시예 등은 본 발명을 예시하기 위한 것이며, 본 발명의 범주가 이들만으로 한정되는 것은 아니다.
Hereinafter, the present invention will be described in further detail with reference to Examples and Experimental Examples. However, the following Examples are intended to illustrate the present invention and the scope of the present invention is not limited thereto.
[실시예 1] 새싹 추출액을 유효성분으로 함유하는 피부 외용제 조성물[Example 1] An external preparation for skin containing a bud extract as an active ingredient
1-1. 새싹 추출액 및 새순 추출액의 제조1-1. Preparation of bud extract and sprout extract
본 실시예는 밀싹, 브로콜리, 유채, 콩싹, 잇꽃, 클로브, 회화나무 꽃봉오리 , 자목련 꽃봉오리 및 차나무 잎의 새싹, 새순 혹은 발아된 식물의 유효성분을 효과적으로 용출하기 위한 것이다.This embodiment is intended to effectively elute the active ingredients of buds, broccoli, oilseeds, sprouts, safflowers, cloves, flower buds, sprout buds, and tea buds, buds or germinated plants.
먼저, 유채, 클로브, 회화나무 꽃봉오리, 자목련 꽃봉오리 및 차나무 잎은 봄 내지 여름철 사이에 새싹을 수확하였으며, 효소 반응 등에 의한 갈변을 방지하기 위하여 영하 20℃ 내지 영하 30℃ 사이에서 냉동 보관하였다. First, oilseed rape, clove, flower buds, siberian buds, and tea leaves were harvested between spring and summer, and stored frozen between minus 20 ° C and minus 30 ° C to prevent browning by enzyme reaction and the like.
다음으로, 밀싹, 브로콜리, 콩싹 및 잇꽃의 경우에는 선별된 씨앗을 6 내지 10시간 정도 물에 불린 후, 배양 용기에 솜을 깔고 씨앗이 겹쳐지지 않게 고르게 뿌린 다음 싹이 트기 전까지 솜이 마르지 않도록 물을 공급하였다. 싹이 2/3 정도 트기 전까지는 검은 천으로 덮어 주었고, 그 이후에는 햇볕을 잘 드는 곳에 방치하였다. 하루에 1 내지 3 회씩 분무기로 물을 뿌려주었고, 3 에서 7 일이 경과한 후 수확하여 영하 20℃ 내지 영하 30℃에서 냉동 보관하였다.Next, in the case of wheat, broccoli, sprouts and safflowers, the selected seeds are soaked in water for about 6 to 10 hours, then the cotton is spread on the culture vessel, the seeds are spread evenly over the non-overlapping seeds, Respectively. The sprouts were covered with a black cloth until about two-thirds of the time, and then they were left in the sunshine. Water was sprayed once or three times a day with a sprayer, and after 3 to 7 days, harvested and kept frozen at minus 20 ° C to minus 30 ° C.
상기의 과정을 통해 준비된 새싹 및 새순들을 분쇄한 후, 메탄올을 용매로 이용하여 추출하였다. 수득된 추출물에서 용매를 증류 제거하여 각 식물의 새싹 추출액을 준비하였다.
The prepared sprouts and larvae were pulverized and then extracted with methanol as a solvent. The solvent was distilled off from the obtained extract to prepare a bud extract of each plant.
1-2. 새싹 추출물을 포함하는 외용제 조성물의 제조1-2. Preparation of composition for external application containing bud extract
상기 실시예 1-1에서 제조한 새싹 및 새순 추출액 100 g에 건조 중량 대비 95% 함수 알코올 100 ml를 첨가하였다. 유효성분이 증발되는 것을 방지하기 위하여 냉각 콘덴서가 장착된 상태에서 50 내지 100℃로 10 시간 가열하여 유효성분을 추출하였다. 추출된 성분을 여과하고 감압 농축한 다음, 이를 건조하여 5 g의 새싹 추출물 및 새순 추출물의 혼합물을 얻었다.To 100 g of the sprout and larvae extract prepared in Example 1-1, 100 ml of 95% hydrous alcohol was added to the dry weight. In order to prevent evaporation of the active ingredient, the active ingredient was extracted by heating at 50 to 100 DEG C for 10 hours in the state that the cooling condenser was mounted. The extracted components were filtered, concentrated under reduced pressure, and then dried to obtain a mixture of 5 g of sprout extract and sprout extract.
얻어진 혼합물을 이용하여, 하기 표 1의 조성으로 피부 외용제 조성물을 제조하였다.Using the obtained mixture, a composition for external application for skin was prepared with the composition shown in Table 1 below.
구체적으로는, 먼저 하기 표 1의 원료 1 내지 6을 혼합하여 70℃에서 용해하고 수상으로 한 다음, 원료 7 내지 14를 70℃에서 용해하여 오일상으로 하였다. 그런 다음, 상기 오일상을 수상에 첨가하고 호모믹서(일본 Tokushu Kika 사)로 교반하여 1차 유화하고, 원료 15를 첨가하여 점증시켰다. 기포를 제거한 후, 실온으로 냉각시켜 조성물을 제조하였다.Concretely, raw materials 1 to 6 shown in Table 1 were first mixed and dissolved at 70 DEG C to form an aqueous phase, and raw materials 7 to 14 were dissolved at 70 DEG C to prepare an oil phase. Then, the oil phase was added to the water phase, followed by primary emulsification with a homomixer (Tokushu Kika, Japan), and then the raw material 15 was added to increase the oil phase. After removing the bubbles, the composition was cooled to room temperature.
[비교예 1][Comparative Example 1]
상기 실시예 1-2와 비교하여, 새싹 및 새순추출물을 첨가하지 않았다는 점을 제외하고는, 동일한 방법으로 외용제 조성물을 제조하였다.
The composition for external application was prepared in the same manner as in Example 1-2, except that no buds and larvae were added.
[실험예 1] 피부 표피 줄기 세포의 활성 증가 관찰[Experimental Example 1] Observation of increased activity of skin epidermal stem cells
인체 표피에서 분리한 각질형성 세포를 24 공 평판배양기에 2 x 105 개의 농도로 넣은 후, 2% 우태아혈청이 들어있는 DMEM 배지에서 배양하였다. 그런 다음, 상기 실시예 1에서 제조한 새싹 및 새순추출물이 각각 50, 500 ppm 농도로 포함된 배지로 교체한 후에 48 시간 동안 배양하였다. The keratinocytes isolated from the human epidermis were placed in a 24-well plate incubator at a concentration of 2 × 10 5 , and then cultured in a DMEM medium containing 2% fetal bovine serum. Then, the buds and larvae extract prepared in Example 1 were replaced with a medium containing 50, 500 ppm, respectively, and cultured for 48 hours.
음성대조군은, 상기 배지에 어떤 새싹 및 새순추출물도 넣지 않은 것이고, 상기배지에 2% 우태아혈청대신 10% 우태아 혈청을 넣은 것으로 양성대조군으로 삼았다. 상층액을 제거하고, 인산 버퍼용액으로 2회 세척을 실시한 후, 세포 분해 버퍼(Cell lysis buffer; 20 mM Tris-HCl(pH 7.4), 250 mM NaCl, 1% Triton X-100) 50 ㎕를 첨가하여 30 분간 정치하였다. 다시 인산 버퍼용액으로 2 회 세척을 실시한 후, 진공장치를 이용하여 나이트로셀룰로오스 멤브레인의 표면에 일정한 양으로 부착시켰다. The negative control group was the one in which no sprout and larvae extract were added to the medium, and 10% fetal bovine serum was added to the medium instead of 2% fetal bovine serum. The supernatant was removed and the cells were washed twice with phosphate buffer solution and then 50 μl of cell lysis buffer (20 mM Tris-HCl (pH 7.4), 250 mM NaCl, 1% Triton X-100) And allowed to stand for 30 minutes. After washing twice with phosphate buffer solution, it was attached to the surface of the nitrocellulose membrane in a constant amount by using a vacuum apparatus.
상기 단백질이 부착된 표면에 블로킹 용액(Blocking solution)으로 2 시간 이상 반응시킨 후, 표피 줄기세포의 대표적인 단백질 마커인 p63의 일차 항체를 블로킹 용액에 1:500으로 현탁하여 1 시간 동안 처리하여 웨스턴 블러팅을 실시하였다.The surface of the protein-coated surface was reacted with a blocking solution for 2 hours or more. The primary antibody of p63, a typical protein marker of epidermal stem cells, was suspended in a blocking solution at a ratio of 1: 500 and treated for 1 hour. .
새싹 및 새순추출물을 넣지 않은 음성대조군과 비교하여, 상대적인 p63 단백질의 발현량을 측정하여 하기 표 2에 나타내었다. The relative expression of p63 protein was measured as compared with the negative control to which no buds and larvae were added, and is shown in Table 2 below.
상기 표 2를 참조하면, 발아 잇꽃의 경우 발현량이 다소 감소하였지만, 7 종의 새싹 및 새순 추출물에 의해 대부분 p63 단백질의 발현량이 증가하였음을 확인할 수 있다. 이는 본 발명에 따른 새싹 및 새순 추출물에 의하여 표피 줄기세포의 활성이 증가된 것을 의미하며, 새싹 및 새순 추출물은 표피의 줄기 세포력을 증진시킬 수 있다는 것을 보여주는 것이다.
Referring to Table 2, although the expression level of germinated safflower was slightly decreased, it was confirmed that the expression level of p63 protein was increased mostly by 7 kinds of buds and larvae extract. This means that the activity of epidermal stem cells is increased by the buds and larvae extract according to the present invention, and the buds and larvae extracts can enhance the epidermal stem cell power.
[실험예 2] 새싹 및 새순 추출물에 의한 피부 세포의 증식 증가 관찰[Experimental Example 2] Observation of increase of skin cell proliferation by buds and larvae extract
2-1. 각질형성 세포의 증식2-1. Proliferation of keratinocytes
인체 표피에서 분리한 각질형성 세포를 96 공 평판배양기에 1 공당 5000 개의 농도로 첨가하고, KGM(keratinocyte growth medium, Lonza) 배지에서 24 시간 배양하였다. 그런 다음, 상기 실시예 1에서 제조한 새싹 및 새순 추출물이 각각 50, 500 ppm 농도로 포함된 KBM(keratinocyte basal medium) 배지로 교체한 후, 48 시간 배양하였다. 여기에 WST-1 용액(Roche)을 1/10배로 넣은 후, 37℃ 인큐베이터에서 2 시간 동안 반응시켰다. 배양이 끝난 평판 배양기는 450 nm에서 발색 정도를 측정하여 세포의 증식 정도를 정량하였다. 그 결과는 하기 표 3에 나타내었다.The keratinocytes isolated from the human epidermis were added to a 96 well plate incubator at a concentration of 5,000 per well and cultured in a KGM (keratinocyte growth medium, Lonza) medium for 24 hours. Then, the buds and larvae prepared in Example 1 were replaced with KBM (keratinocyte basal medium) containing 50 and 500 ppm, respectively, and cultured for 48 hours. The WST-1 solution (Roche) was added thereto at a ratio of 1/10, followed by reaction at 37 ° C for 2 hours in an incubator. The cell culture was quantitated by measuring the degree of color development at 450 nm in the incubated plate incubator. The results are shown in Table 3 below.
상기 표 3을 참조하면, 7 가지 추출물 각각에서 각질형성 세포의 증식이 촉진되었음을 알 수 있다. 각각의 새싹 및 새순추출물 모두 각질형성 세포의 증식을 대략 105 내지 180%의 범위에서 증가시키는 것을 확인하였다.
Referring to Table 3, it can be seen that the proliferation of keratinocytes was promoted in each of the seven extracts. It was confirmed that the growth of keratinocytes in each of the buds and larvae was increased in the range of approximately 105 to 180%.
2-2. 섬유아세포의 증식2-2. Proliferation of fibroblasts
인체의 진피에서 분리한 섬유아세포를 96 공 평판배양기에 1 공당 5000 개의 농도로 각각 24 시간 키운 후, 10% 우태아혈청이 들어있는 DMEM 배지(Welgene)에서 24 시간 배양하였다. 그런 다음, 새싹 및 새순 추출물이 각각 50, 500 ppm 농도로 포함된 1% 우태아혈청이 들어있는 DMEM 배지 배지로 교체한 후, 48 시간 배양하였다. 여기에 WST-1 용액(Roche)을 1/10배로 넣은 후, 37℃ 인큐베이터에서 2 시간 동안 반응시켰다. 배양이 끝난 평판 배양기는 450 nm에서 발색 정도를 측정하여, 세포의 증식 정도를 정량하였다. 그 결과를 하기 표 4에 나타내었다.
The fibroblasts isolated from the human dermis were cultivated in a 96 well plate incubator for 24 hours at a concentration of 5000 per well and then cultured in DMEM medium (Welgene) containing 10% fetal bovine serum for 24 hours. Then, the buds and larvae extracts were replaced with DMEM medium containing 1% fetal bovine serum containing 50 and 500 ppm, respectively, and cultured for 48 hours. The WST-1 solution (Roche) was added thereto at a ratio of 1/10, followed by reaction at 37 ° C for 2 hours in an incubator. In the incubated plate incubator, the extent of cell proliferation was determined by measuring the degree of color development at 450 nm. The results are shown in Table 4 below.
상기 표 4를 참조하면, 유채 새싹을 제외한 6 가지 추출물 각각에서 섬유아세포의 증식이 촉진되었음을 알 수 있다. 상기 새싹 및 새순 추출물에 의하여 대략 105 내지 130%의 범위에서 섬유아세포의 증식이 증가되었음을 확인하였다.
Referring to Table 4, it can be seen that fibroblast proliferation was promoted in each of the six extracts except rapeseed. It was confirmed that the proliferation of the fibroblasts was increased in the range of about 105 to 130% by the buds and larvae extracts.
[실험예 3] 무모생쥐 광노화 동물모델을 이용한 콜라겐 감소 억제 확인[Experimental Example 3] Confirmation of suppression of collagen reduction by using a mouse model
실제 자외선에 의한 피부 주름 콜라겐 분해 억제 효능을 알아보기 위해서 약 7주령의 무모생쥐(SKH-1 female hairless mouse)를 이용하여 도포시험을 실시하였다. 상기의 표 1에서와 같이 새싹 및 새순 추출물 7종이 복합되어 함유된 실시예 1 및 비교예 1을 조제하여 무모생쥐의 등부위에 자외선조사와 함께 11주간 도포하였다. In order to investigate the effect of skin wrinkle collagen degradation by ultraviolet rays, a coating test was carried out using a SKH-1 female hairless mouse at about 7 weeks of age. As shown in Table 1, Example 1 and Comparative Example 1 in which seven buds and larvae extracts were mixed were prepared and applied to the back of hairless mice for 11 weeks together with ultraviolet irradiation.
자외선 조사는 격일로, 물질도포는 매일 진행하였고 또한 물질 도포가 끝난 후 무모생쥐의 등부위 피부를 생검하여 단백질을 얻은 후 콜라겐에 대한 웨스턴 블라팅(western blotting) 실험을 통해 자외선에 의한 콜라겐 감소 억제 효과를 확인하였으며, 그 결과는 도 1에 나타내었다.Ultraviolet irradiation was carried out every other day, and material application was carried out on a daily basis. After completion of the substance application, the skin of the back of the hairless mouse was biopsied to obtain proteins, and then the western blotting test for collagen was carried out to suppress collagen reduction by ultraviolet The results are shown in Fig.
도 1을 통해, 7종의 새싹 및 새순추출물을 함께 복합으로 처리한 경우가 대조군(비교예)에 비해 자외선에 의한 피부 내 콜라겐 감소가 회복됨을 확인할 수 있었다.1, it was confirmed that collagen reduction in the skin due to ultraviolet rays was restored when the combined treatment of seven kinds of buds and larvae extracts was compared with the control (Comparative Example).
상기 실험예들의 결과를 종합하면, 본 발명에 따른 새싹 추출물을 함유한 조성물은 피부 표피 줄기 세포의 활성을 증가시키고, 표피의 각질형성 세포와 진피의 섬유아세포의 세포 증식을 증진하는 효과가 있다. According to the results of the above experimental examples, the composition containing the extract of the sprouts according to the present invention increases the activity of skin epidermal stem cells and promotes cell proliferation of epidermal keratinocytes and dermal fibroblasts.
또한, 노화방지의 하나의 기작인 항산화 효능도 인정되며, 일실시예에 따른 7종을 복합적으로 사용시 콜라젠의 분해가 지연됨을 확인할 수 있었다. 이러한 피부세포의 증식과 줄기세포 활성의 증진은 피부주름 및 탄력개선을 통해 피부 노화방지 및 개선에 효과적인 물질로 활용할 수 있음을 보여주는 것이다.In addition, the antioxidant effect, which is one mechanism of anti-aging, was also recognized, and it was confirmed that decomposition of collagen was delayed when 7 kinds according to one embodiment were used in combination. Such proliferation of the skin cells and promotion of the stem cell activity show that it can be used as an effective material for prevention and improvement of skin aging by improving the wrinkles and elasticity of the skin.
아울러 본 발명은 알로에 잎 추출물, 병풀 추출물 및 연교 추출물을 피부 외용 조성물에 함유시킬 수 있다. In addition, the present invention can contain the aloe leaf extract, centilla callus extract, and tangle extract in a composition for external application to the skin.
여기서 알로에는 다당류, 아미노산, 비타민, 탄닌 등 여러 성분이 혼합되어 있고, 특히 다당류는 피부보습성이 뛰어나므로 항상 일정한 수분을 유지시켜 주는 작용을 하게 되는데, 알로에의 젤리질은 단당류와 포도당과 만노스의 분자로 된 겔이 외피의 죽은 세포를 밀착시키는 접착성을 가지고 있어서 차단막을 형성하여 외부로부터 피부에 침투하는 이물질을 막아주어 피부손상을 방지하고, 수분의 발산을 막아주어 피부를 촉촉하게 해 준다.Here, aloe is mixed with various components such as polysaccharides, amino acids, vitamins, and tannins. Particularly polysaccharides are excellent in skin moisturizing properties, so they always function to maintain a constant water. Aloe's gelatinizes the molecules of monosaccharide, glucose and mannose Has a sticky adhesion to the dead cells of the outer skin to form a barrier to prevent foreign matter penetrating from the outside to prevent skin damage and moisturize the skin.
상기 알로에는 순수한 천연 알로에의 신선한 초록 잎에서 추출하게 되며 이렇게 추출된 알로에의 젤리질은 피부를 깨끗하게 해주며, 피부에 영양과 수분을 공급하고, 염증과 습진을 치료해 주고 피부 재생과 미백 효과, 혈액 순환을 촉진하고 주름을 없애 주는 기능을 복합적으로 수행한다The aloe is extracted from the fresh green leaves of pure natural aloe. The extracted aloe jelly cleanses the skin, nourishes and moisturizes the skin, treats inflammation and eczema, and regenerates and whitens skin, blood circulation And to remove wrinkles.
이에 따라 상기 알로에 잎 추출물을 피부 외용제 조성물에 함유하면 알로에의 보습, 면역조절 작용, 상처치유 작용, 항균/항바이러스 작용 등을 수득할 수 있다. Accordingly, when the aloe leaf extract is contained in the composition for external application for skin, aloe moisturizing, immunomodulating action, wound healing action, antibacterial / antiviral action and the like can be obtained.
또한 병풀 추출물은 오랫동안 민간 치료제로서 사용되어 왔는데, 상처 치유에 탁월한 효과가 있는 것으로 알려져 있고, 고대 인디언들은 피부가 거칠어 보일 때는 매일 병풀 잎을 두 장씩 먹었다고 전해진다. 또한, 병풀 추출물은 외과적 상처나 2-3도 화상에 매우 효과적인 치료제로서 사용되고 있다. 외상의 경우, 피부질환으로 생긴 상처에 아시아티코시드(asiaticoside)가 0.5-1.0% 함유된 연고를 처방하거나, 2%의 아시아티코시드가 추천 용량이며, 하루 한두 번으로 치료가 된다고 한다.It has also been known for a long time that it has been used as a cure for civilian disease. It is said that it has an excellent effect on wound healing, and ancient Indians are said to have eaten two sheets of leaflings every day when their skin is rough. In addition, Centella asiatica extract is used as a therapeutic agent which is very effective for surgical scratches and 2-3 degree burns. In the case of trauma, prescribe ointment containing 0.5-1.0% of asiaticoside to the wound caused by the skin disease, or 2% of the Asian ticoside is recommended dose and it is treated with one or two times a day.
병풀의 학명은 센텔라 아시아티카(Centella asiatica)이며, 이것은 콜라겐의 합성을 촉진시킨다고 밝혀졌다. 병풀 추출물은 콜라겐과 피브로넥틴에 의한 진피의 상처치유 효과를 나타낸다는 것이 쥐 실험 결과 밝혀졌다.Centella asiatica is the scientific name of the plant, which has been shown to promote the synthesis of collagen. The results of a rat experiment revealed that the centilla extract showed a wound healing effect of collagen and fibronectin in the dermis.
피부 관리의 측면에서는 노화된 피부의 재생을 도와주는 중요한 작용을 한다. 특히, 제품에 병풀 추출물이 함유된 것은 가려움과 자극을 조율하는 역할을 한다고 알려져 있다.In terms of skin care, it plays an important role in helping the regeneration of aged skin. Especially, it is known that the product contains the centilla extract, which plays a role in coordinating itching and irritation.
특히, 본 발명에서는 병풀 발효 추출물을 사용하는 것이 바람직하며, 병풀 발효 추출물을 얻는 방법은 다음과 같다. 먼저, 병풀 잎과 뿌리를 세척하여 분쇄한다. 그 다음, 공기가 투과되고 액체성분은 투과되지 않는 도기재질의 반응기에 분쇄물을 주입한 다음, 25-28℃의 상온에서 72시간 방치하여 발효시킨다. 이러한 발효에 의해서 병풀 분쇄물은 고/액 분리된다. 상기 고/액 분리된 병풀 발효물을 여과기에 의해 여과하여 병풀 발효 추출물을 획득한다.In particular, in the present invention, it is preferable to use a wisteria fermentation extract, and a method for obtaining a wisteria fermentation extract is as follows. First, the leaflings and roots are washed and pulverized. Next, the pulverized material is injected into a ceramic material-made reactor in which air is permeated and the liquid component is not permeated, and then fermented by allowing it to stand at 25-28 캜 for 72 hours. By this fermentation, the pulverized seedlings are subjected to solid / liquid separation. The above fermented product of the Wakulpul isolate is filtered by a filter to obtain a Wakopulse fermented extract.
이와 같은 본 발명의 병풀 추출물이 포함됨에 따라 상처치유 작용과 , 콜라겐 합성 작용, 항염작용, 항균작용 등이 보다 유도될 수 있게 된다. The inclusion of the centilla sprout extract of the present invention enables wound healing, collagen synthesis, anti-inflammation, and antibacterial activity to be further induced.
아울러 연교는 물푸레나무과 (Oleaceae)식물인 개나리 (Fors- ythia)의 열매 추출물이며, 한방에서 나력, 옹종, 악창, 영류, 결열,고독을 주로 치료하고 창절배농과 지통을 하며 오림과 소변불통 및 심의 객열, 해독, 배농, 소염에 이용하며, 현대 의학에서는 c-AMP 포스포디에스터라제 작용 억제, 황색 포도상 구균에 대한 항균작용 등에 사용된다.In addition, it is a fruit extract of Forsythia which is an Oleaceae plant. It mainly treats herbaceous, herbaceous, vulgaris, malaria, hypertrophy and solitary herpes in a herb, Detoxification, drainage, and anti-inflammation. In modern medicine, c-AMP phosphodiesterase is inhibited and used for antibacterial activity against Staphylococcus aureus.
또한 연교의 성분으로는 리그난스(Lignans), 피노레시놀(Pinoresinol), 피노레시놀 글루코시드 마타이레시노사이드(Pinoresirnol glucoside Matairesinoside), 마타이레시놀(Matairesinol), 필리린(Phillyrin), 악티게닌(Arctigenin), 악틴(Arctiin), 카페오일 글리코시드(Caffeoyl glycoside), 포티아시드(Forthiaside), 수센소시드(Susensoside), 악테오시드(Acteoside), 비리디시마시드(Viridissimaside), 아세틸오레아놀릭산(Acetyloleanolic acid), 베투린(Betulin), 비리디시믹산(Viridissimic acid), 오레아놀릭산(Oleanolic acid), 베투릭산(Betulinic acid), 루틴(Rutin), 우솔릭산(Ursolic acid) 등이다.In addition, the components of the allium include Lignans, Pinoresinol, Pinoresirnol glucoside Matairesinoside, Matairesinol, Phillyrin, Arctigenin, Caffeoyl glycoside, Forthiaside, Susensoside, Acteoside, Viridissimaside, Acetyl Oleanolic Acid (" Acetyloleanolic acid, Betulin, Viridissimic acid, Oleanolic acid, Betulinic acid, Rutin, Ursolic acid and the like.
상기 연교 추출물은 건조된 연교를 탄소수 1∼3의 무수 또는 함수 알코올, 또는 에틸 아세테이트로 4∼30℃에서 3∼20일간 추출한 다음, 농축하여 제조할 수 있다.The almond extract may be prepared by extracting dried almonds with an anhydrous or hydrolyzed alcohol having 1 to 3 carbon atoms or ethyl acetate at 4 to 30 ° C for 3 to 20 days, followed by concentration.
또한, 상기 연교 추출물은 연교를 물, 탄소수 1∼3의 무수 또는 함수 알코올, 또는 에틸 아세테이트로 50∼100℃에서 3∼24시간 동안 추출한 다음, 농축하여 제조할 수 있다.The almond extract can be prepared by extracting the allylate with water, anhydrous or hydrous alcohol having 1 to 3 carbon atoms or ethyl acetate at 50 to 100 ° C for 3 to 24 hours, and then concentrating.
이러한 연교 추출물을 본 발명에 따른 피부 외용제 조성물에 함유시킴으로써 항노화, 항염, 청열해독, 해열소염 등이 효과를 유도할 수 있게 된다.
By incorporating such a tangle extract into the composition for external application for skin according to the present invention, anti-aging, anti-inflammation, cyanotic detoxification, and antipyretic effect can be induced.
이와 같이 본 발명은 도면에 도시된 일실시예를 참고로 설명되었으나, 이는 예시적인 것에 불과하며, 본 기술 분야의 통상의 지식을 가진 자라면 이로부터 다양한 변형 및 균등한 타 실시예가 가능하다는 점을 이해할 것이다. While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to those precise embodiments, and many alternatives, modifications, and variations will be apparent to those skilled in the art. I will understand.
따라서, 본 발명의 진정한 기술적 보호범위는 첨부된 특허청구범위의 기술적 사상에 의해 정해져야 할 것이다.
Accordingly, the true scope of the present invention should be determined by the technical idea of the appended claims.
Claims (8)
As an active ingredient, a sprout extract composed of a bud sprout extract, a broccoli sprout extract, a rape bud sprout extract, a bud sprout extract, a safflower sprout extract and a clove sprout extract, a sprout extract of a flower bud, a sprout bud sprout extract and a tea leaf sprout extract A composition comprising a sprout extract and a sprout extract containing a sprout extract.
상기 새싹추출물은 밀싹 새싹추출물, 브로콜리 새싹추출물, 유채 새싹추출물, 콩싹 새싹추출물, 잇꽃 새싹추출물 및 클로브 새싹추출물을 1~5 : 1~5 : 1~5 : 1~5 : 1~5 : 1~5의 중량비로 함유한 새싹추출물 및 새순추출물을 이용한 피부 외용제 조성물.
The method according to claim 1,
The sprout extracts can be used in an amount of 1: 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1, 5 < tb >< SEP >
상기 새순추출물은 회화나무 꽃봉오리 새순추출물, 자목련 꽃봉오리 새순추출물 및 차나무 잎 새순추출물을 1~5 : 1~5 : 1~5의 중량비로 함유한 새싹추출물 및 새순추출물을 이용한 피부 외용제 조성물.
The method according to claim 1,
The composition for external application for skin according to any one of claims 1 to 5, wherein the extract is a bud extract and the extract is from 1 to 5: 1 to 5: 1 to 5 parts by weight, based on the total weight of the extract.
상기 피부 외용제 조성물은,
새싹추출물과 새순추출물이 1~2 : 1~2의 중량비로 함유된 새싹추출물 및 새순추출물을 이용한 피부 외용제 조성물.
The method according to claim 1,
The composition for external application for skin,
A composition for external application for skin using a bud extract and a sprout extract, wherein the sprout extract and the sprout extract are contained in a weight ratio of 1: 2 to 1: 2.
상기 새싹추출물 및 새순추출물의 총 중량은 조성물 총 중량에 대하여 0.001 내지 10 중량%로 포함된 새싹추출물 및 새순추출물을 이용한 피부 외용제 조성물.
5. The method of claim 4,
Wherein the total weight of the bud extract and the bud extract is in the range of 0.001 to 10% by weight based on the total weight of the composition.
상기 새싹추출물 및 새순추출물은 열수, C1 -4의 저급 알코올 또는 이들의 혼합 용매에 온침으로 추출, 여과하고 감압 농축하여 제조된 새싹추출물 및 새순추출물을 이용한 피부 외용제 조성물.
The method according to claim 1,
The composition for external application for skin using sprout extract and sprout extract prepared by extracting, filtering and concentrating under reduced pressure on hot water, C 1 -4 lower alcohol or a mixture thereof,
상기 피부 외용제 조성물은 유연화장수, 영양화장수, 마사지크림, 영양크림, 팩, 젤 또는 피부 점착타입 화장료의 제형이거나, 로션, 연고, 겔, 크림, 패취 또는 분무제인 새싹추출물 및 새순추출물을 이용한 피부 외용제 조성물.
The method according to claim 1,
The composition for external application for skin may be a formulation of a softening agent, a nutritional lotion, a massage cream, a nutritional cream, a pack, a gel or a skin adhesive type cosmetic or a skin external application using a lotion, ointment, gel, cream, patch or spray extract Composition.
상기 피부 외용 조성물은
알로에 잎 추출물, 병풀 추출물 및 연교 추출물 중 선택되는 어느 하나 이상을 더 함유하는 새싹추출물 및 새순추출물을 이용한 피부 외용제 조성물.
The method according to claim 1,
The external skin composition
Wherein the composition further comprises at least one selected from the group consisting of Aloe leaf extract, Centella asiatica, Centella asiatica extract, and Seaweed extract.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120072130A KR101420211B1 (en) | 2012-07-03 | 2012-07-03 | Skin Composition for External Application Using Bud and Sprout Extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120072130A KR101420211B1 (en) | 2012-07-03 | 2012-07-03 | Skin Composition for External Application Using Bud and Sprout Extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20140004463A KR20140004463A (en) | 2014-01-13 |
KR101420211B1 true KR101420211B1 (en) | 2014-07-17 |
Family
ID=50140445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120072130A Active KR101420211B1 (en) | 2012-07-03 | 2012-07-03 | Skin Composition for External Application Using Bud and Sprout Extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101420211B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220107758A (en) * | 2021-01-26 | 2022-08-02 | 코스맥스 주식회사 | Cosmetic composition comprising Sprout extracts |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101666021B1 (en) | 2016-02-23 | 2016-10-24 | 주태영 | Broccoli sprout tea and manufacturing method thereof |
KR101965391B1 (en) | 2018-04-17 | 2019-04-03 | 주태영 | Broccoli Sprout Extract with Enhanced Sulforaphane and Manufacturing Method Thereof |
KR102081984B1 (en) * | 2018-04-20 | 2020-02-26 | 대한민국 | A pharmaceutical composition comprising extract from wheat sprowt for preventing or treating osteoporosis |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19990050827A (en) * | 1997-12-17 | 1999-07-05 | 서경배 | Skin composition containing natural fragrances effective for acne |
KR20060025630A (en) * | 2004-09-17 | 2006-03-22 | 주식회사 엘지생활건강 | Skin improvement cosmetic composition containing sprout extract |
KR20110092971A (en) * | 2010-02-11 | 2011-08-18 | 웅진코웨이주식회사 | Mixed extract having antioxidant and anti-inflammatory effects and cosmetic composition comprising the same |
KR20120041090A (en) * | 2009-03-30 | 2012-04-30 | 가부시키가이샤 시세이도 | Fibroblast proliferator |
-
2012
- 2012-07-03 KR KR1020120072130A patent/KR101420211B1/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19990050827A (en) * | 1997-12-17 | 1999-07-05 | 서경배 | Skin composition containing natural fragrances effective for acne |
KR20060025630A (en) * | 2004-09-17 | 2006-03-22 | 주식회사 엘지생활건강 | Skin improvement cosmetic composition containing sprout extract |
KR20120041090A (en) * | 2009-03-30 | 2012-04-30 | 가부시키가이샤 시세이도 | Fibroblast proliferator |
KR20110092971A (en) * | 2010-02-11 | 2011-08-18 | 웅진코웨이주식회사 | Mixed extract having antioxidant and anti-inflammatory effects and cosmetic composition comprising the same |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220107758A (en) * | 2021-01-26 | 2022-08-02 | 코스맥스 주식회사 | Cosmetic composition comprising Sprout extracts |
KR102609692B1 (en) | 2021-01-26 | 2023-12-05 | 코스맥스 주식회사 | Cosmetic composition comprising Sprout extracts |
Also Published As
Publication number | Publication date |
---|---|
KR20140004463A (en) | 2014-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101059471B1 (en) | Cosmetic composition for skin aging | |
KR101393007B1 (en) | Cosmetic Composition for Skin-aging Protection and Wrinkle Improvement Comprising the Extract of Nephelium lappaceum and Litchi chinensis sonn as Active Ingredient | |
KR101828584B1 (en) | Composition containing complex extracts including Veratrum nigrum var. ussuriense, Juglans mandshurica, Rodgersia podophylla and Chaenomeles sinensis with antioxidant activity or whitening | |
Dhingra et al. | Review on phytochemical constituents and pharmacological activities of plant Calendula officinalis Linn. | |
KR101502687B1 (en) | Anti-aging and Anti-inflammatory and Anti-oxidant Cosmetic Composition including Beans Placenta Cell Cultures Extracts | |
KR101082272B1 (en) | Composition for inhibiting aging containing extracts from plant buds | |
KR101677466B1 (en) | Anti-wrinkle Cosmetic Composition Comprising Hylocereus undatus (Haw.) Britt. and Rose Extract | |
KR20150064314A (en) | Cosmetic Composition Comprising Mangifera indica L. Extract, Passiflora edulis Sims Extract, Hylocereus undatus (Haw.) Britt. and Rose Extract, Actinidia chinensis Planch. Extract and Annona Squamosa Extract | |
WO2012002783A2 (en) | Skin-whitening composition containing extracts from trees including paper mulberry | |
KR100443588B1 (en) | Cosmetic composition containing paeonia suffruticosa andrews extract and albizzia julibrissin dura extract having anti-ageing effect | |
KR101420211B1 (en) | Skin Composition for External Application Using Bud and Sprout Extract | |
KR101822092B1 (en) | Cosmetic composition for preventing thermal skin aging containing aloe vera leaves complex extract | |
KR101930264B1 (en) | Cosmetic composition for inhibiting secretion of sebum and for improving acne symptoms containing natural complex extract | |
KR20120092229A (en) | Cosmetic composition comprising the fermented extracts of tissue cultures of brassica napus l, punica granatum and panax ginseng) | |
KR20100130877A (en) | Composition having skin irritation and irritant effect | |
KR20110032715A (en) | Anti-aging cosmetic composition and preparation method thereof | |
KR102154139B1 (en) | Composition comprising fermentation of sap of painted maple, cacao nibs extract and granat extract | |
KR101662805B1 (en) | extract of rice bran reinforced vitamin and cosmetic composition and manufacturing method thereof | |
KR20100092922A (en) | A skin whintening cosmetic composition containing a oriental herb extracts mixture stabilized by nanoliposome | |
KR102119316B1 (en) | Cosmetic composition containing Paeonia suffruticosa complex extract | |
KR101888133B1 (en) | Composition For Promoting Synthesis of Collagen and Cosmetic Composition Using Extracts of Roots of Chrysanthemum indicum | |
KR102692062B1 (en) | A cosmetic composition having anti-oxidant, anti-inflammatory, protection of skin cell induced by ultraviolet ray and skin whitening effects comrising camellia sinensis extract, rumex crispus extract and inula britannica extract | |
KR100529542B1 (en) | Extraction method of a effective component of a cosmetic, composition of cosmetic and a cosmetic | |
KR102168531B1 (en) | Cosmetic composition for enhancing skin elasticity or improving skin wrinkle containing herb extracts | |
KR20150052907A (en) | Cosmetic composition for Improving Skin Moisturization Comprising the mixed extract of Peach blossom, Sophora japonica flower, Rhubarb and Clove buds as active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20120703 |
|
PA0201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20130905 Patent event code: PE09021S01D |
|
PG1501 | Laying open of application | ||
E90F | Notification of reason for final refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20140321 Patent event code: PE09021S02D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20140627 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20140710 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20140710 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20170810 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20170810 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20180710 Year of fee payment: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20180710 Start annual number: 5 End annual number: 5 |
|
FPAY | Annual fee payment |
Payment date: 20190710 Year of fee payment: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20190710 Start annual number: 6 End annual number: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20210712 Start annual number: 8 End annual number: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20220711 Start annual number: 9 End annual number: 9 |
|
PR1001 | Payment of annual fee |
Payment date: 20230710 Start annual number: 10 End annual number: 10 |
|
PR1001 | Payment of annual fee |
Payment date: 20240710 Start annual number: 11 End annual number: 11 |